Risk management for people with inherited BRIP1 mutations
The National Comprehensive Cancer Network (NCCN) provides risk management guidelines for people with BRIP1 mutations. We recommend that you speak with a genetics expert who can look at your personal and family history of cancer and can help you determine the best risk-management plan. You can learn more about risk management options in our section on Screening and Risk Reduction by Cancer Type.
People with a BRIP1 mutation may also qualify for clinical trials looking for more effective screening or prevention for cancer.
Ovarian cancer prevention
The National Comprehensive Cancer Network (NCCN) guidelines recommend that women with a BRIP1 mutation consider risk-reducing salpingo-oophorectomy (removal of their ovaries and fallopian tubes) between the ages of 45-50 or earlier if there is a family history of an earlier ovarian cancer.
Other cancer screening and prevention
There has not been enough research to show a benefit from screening and prevention for other cancers in people who have a BRIP1 mutation. For this reason, experts recommend managing these risks based on family history of cancer. Cancer screening and prevention research studies may be available for people with BRIP1 mutations.
If you are a person with an BRIP1 mutation making decisions about managing your cancer risk, you can find peer support through the following resources:
- Register for the FORCE Message Boards to connect with others who share your situation.
- FORCE's Peer Navigation Program will match you with a volunteer who shares your mutation and situation and provide you with a free resource guide.
- Contact the FORCE impact leaders in your area to link to local support groups and other resources.
- Attend a virtual support meeting in your area.
- Read the stories from members of our community.
The following screening and prevention studies are open to people with a BRIP1 mutation.
- NCT03805919: Men at High Genetic Risk for Prostate Cancer. This is a prostate cancer screening study using MRI in high risk men. This study is open to men with an inherited BRIP1 or other mutation.
- Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.